DocWire News Editors

DocwireNews

Cost and savings will ultimately play a key role in determining the acceptance of biosimilars, and in coming years, biosimilars are expected to increase market competition, thereby diminishing health care costs. In this review, published in Pharmacy &amp; Therapeutics, authors examined key considerations about biosimilars that U.S. payers should take into consideration, exploring the uptake of biosimilars, the current U.S. inexperience with biosimilars, cost consideration, and value beyond price.The main uptake of biosimilars is likely due to acquisition costs. These projected reductions in acquisition costs in the United States range from 10% to 20%. Although this is lower than the reduction seen over time with generic drugs, the significance in terms of absolute savings may be similar, owing to the higher cost of reference products. However, there are other factors to consider for buyers deciding to select a biosimilar over the biologic originator or over another biosimilar of the same reference. For all stakeholders, the quality, efficacy, and safety of the biosimilar is paramount, while factors to consider for health care professionals, and payers include manufacturer reliability, reimbursement rates (set by either Medicare of commercial payers), and any support services made available for both patients and physicians alike. Patients are heavily influenced by their providers, whom they trust to supply accurate information of the efficacy and safety of their medications, while also striving to mitigate any out-of-pocket expenses they may incur. The impact of patient expenses often correlates to adherence, which can potentially affect clinical outcomes.Payers should also be aware that despite the expected differences in unit cost between biosimilars and their original references, they may still need to negotiate with manufacturers to push the projected savings beyond the original. For patients enrolled in Medicare Part B, recipients are reimbursed the value of a biosimilar based on the sum of the drug&rsquo;s average selling price plus a fixed percentage, currently 6%, of the originator&rsquo;s price. This stipulation is intended to put Medicare payments for biosimilars on a level playing field with the refence products. The decreased acquisition costs of biosimilars compared to originators stand to affect patients with high-deductible plans or coinsurance where their expenses are calculated as a percentage rather than a fixed copay. Such patients may drive their providers to prescribe biosimilars over the reference product to mitigate expenditures.One obstacle standing in the way of further biosimilar uptake is the relative inexperience of stakeholders in the US in dealing with these drugs. The major considerations payers should consider include provider and patient education and gaining an understanding of the regulatory approval process. This includes learning about differences in state and regional adoption practices and laws, administration strategies, and insurance coverage barriers. The authors noted vthat &ldquo;educational opportunities for physicians, patients, and payers are needed to facilitate the incorporation of biosimilars into formulary decision-making.&rdquo;Overall, there are many important factors that payers should evaluate when considering biosimilars. The authors concluded by urging payers to &ldquo;consider the impact of state laws regarding substitution, including how interchangeable biosimilars may be used.&rdquo; They added that when it comes to the U.S., &ldquo;further real-world experience with biosimilars is needed to more fully appreciate their broader value and potential for increasing patient access to life-saving biologics.&rdquo;

Connie Rhee, MD

Joel M. Topf, MD, FACP

CKD Management and Cognition

NKF Spring Clinical Meetings 2025

Bradley Marder, MD

Gout Studies: Transplant Waitlisting and Bone Erosion

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Latest News

Biosimilars: Considerations for Payers

Oncology

Cost and savings will ultimately play a key role in determining the acceptance of biosimilars, and in coming years, biosimilars are expected to increase market competition, ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe